-
Ask the MD: Pain and Parkinson's Disease
February 22, 2017
… is not working optimally and Parkinson's symptoms return. Dyskinesia : Dyskinesia is abnormal, involuntary movement that may …
-
Michael J. Fox Foundation Awards $3.8 Million to Drive Nine Industry Partnerships for Pre-Clinical Parkinson's Drug Development
July 21, 2009
… receptor compounds on treatment of levodopa-induced dyskinesia in Parkinson’s disease Kristen Jordan, PhD, … of MOR antagonists for the treatment of L-DOPA-induced dyskinesias in Parkinson’s disease Patrick Little, PhD, …
-
Targeting Beta-arrestin Signaling in the Treatment of Parkinson's Disease
… and determine their possible role in the manifestation of dyskinesia. Project Description: To test our hypotheses, we … treatment are mediated by beta-arrestin2 signaling, whereas dyskinesias result from the classical G protein-dependent …
-
The Michael J. Fox Foundation Directs $1 Million to Study Side Effect of Parkinson's Therapy
September 16, 2003
… $1 million to fund five projects that will investigate dyskinesias, the involuntary, uncontrollable movements that …
-
Gocovri (amantadine extended release)
… the first drug specifically indicated for levodopa-induced dyskinesia (irregular, involuntary, uncontrolled … supporting the creation and authentication of the Unified Dyskinesia Rating Scale , a tool that was used to measure …
-
What We Fund: $21 Million to Ease Symptoms, Profile Genes and Test for the “Parkinson’s Scent"
August 30, 2021
… Therapeutics is studying a protein that may play a role in dyskinesia , uncontrollable movements. Dyskinesia arises from unbalanced brain activity in a region …